BMS signs up-to-$15.2B 13-pipeline megadeal with China's Hengrui

Bristol Myers Squibb signed a global licensing and co-development agreement with Hengrui on May 12 covering 13 early-stage oncology, hematology, and immunology programs. The deal includes a $600M upfront payment and up to $950M in near-term payments, with total potential value reaching $15.2B including milestones and royalties. Hengrui's Hong Kong-listed shares jumped more than 13%.